ViiV boosted by Phase IIa data for VH184 and VH499
ViiV Healthcare has announced promising results from two Phase IIa studies of investigational antiretroviral therapies, VH184 and VH499.
ViiV, a specialist HIV company majority owned by GSK (LSE: GSK) with Pfizer (NYSE: PFE) and Shionogi (TYO: 4507) as shareholders, presented the data at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.
VH184, a third-generation integrase inhibitor, demonstrated strong antiviral activity across multiple dose levels in individuals with HIV-1. No drug resistance mutations were observed, and all side effects were mild to moderate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze